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Purpose: We evaluate a novel magnetic resonance imaging (MRI) technique to improve
detection of aggressive prostate cancer (PCa).
Materials and Methods: We performed a retrospective analysis of pre-surgical prostate
MRI scans using an advanced diffusion-weighted imaging technique called restriction spec-
trum imaging (RSI), which can be presented as a normalized z -score statistic. Scans were
acquired prior to radical prostatectomy. Prostatectomy specimens were processed using
whole-mount sectioning and regions of interest (ROIs) were drawn around individual PCa
tumors. Corresponding ROIs were drawn on the MRI imaging and paired with ROIs in
regions with no pathology. RSI z -score and conventional apparent diffusion coefficient
(ADC) values were recorded for each ROI. Paired t -test, ANOVA, and logistic regression
analyses were performed.
Results: We evaluated 28 patients with 64 ROIs (28 benign and 36 PCa). The mean dif-
ference in RSI z -score (PCa ROI–Benign ROI) was 2.17 (SE=0.11; p<0.001) and in ADC
was 551 mm2/s (SE=80 mm2/s; paired t -test, p<0.001). The differences in the means
among all groups (benign, primary Gleason 3, and primary Gleason 4) was significant for
both RSI z -score (F 3,64=97.7, p<0.001) and ADC (F 3,64=13.9, p<0.001). A t -test was
performed on only PCa tumor ROIs (n=36) to determine PCa aggressiveness (Gleason
3 vs. Gleason 4) revealing that RSI z -score was still significant (p=0.03), whereas, ADC
values were no longer significant (p=0.08). In multivariable analysis adjusting for age and
race, RSI z -score was associated with PCa aggressiveness (OR 10.3, 95% CI: 1.4–78.0,
p=0.02) while ADC trended to significance (p=0.07).
Conclusion: The RSI-derived normalized cellularity index is associated with aggressive
PCa as determined by pathologic Gleason scores. Further utilization of RSI techniques may
serve to enhance standardized reporting systems for PCa in the future.
Keywords: prostate, MRI imaging, prostate cancer, cellularity, Gleason score
INTRODUCTION
One current focus in prostate cancer (PCa) diagnosis is to
distinguish indolent from more aggressive disease to reduce
over-treatment (1, 2). Magnetic resonance imaging (MRI) may
be a non-invasive imaging biomarker to incorporate into PCa
detection and treatment strategies (3).
Recently,MRI has been increasingly investigated for use as a tool
in the screening, staging, and monitoring of PCa (4–6). Imaging
techniques such as diffusion-weighted imaging (DWI) and the
resultant quantitative apparent diffusion coefficient (ADC) have
shown correlation with PCa; however, they have significant limita-
tions regarding tumor conspicuity and localization (7, 8). A novel,
advanced diffusion-based imaging technique, called restriction
spectrum imaging (RSI), has been modified from previous studies
in brain cancer detection to apply to patients with PCa (8, 9). Some
benefits of the RSI technique include reduced spatial distortion,
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enhanced tumor contrast-to-noise over conventional diffusion-
weighted imaging (DWI), and a normalized in vivo measure of
cellularity.
Within individual tumor regions of interest (ROIs), we investi-
gate the association of final pathologic Gleason score from whole-
mount prostatectomy specimens with the RSI cellularity index as
compared to the current standard, ADC (10–16). Our primary
outcome is the detection of primary pattern Gleason ≥4 PCa.
MATERIALS AND METHODS
PATIENTS
All patients were previously diagnosed with PCa via standard tran-
srectal ultrasound guided prostate biopsy after prostate specific
antigen (PSA) elevation or abnormal digital rectal examination
(DRE). Pre-surgical pelvic MRI is routinely used at our institu-
tion to identify extraprostatic extension (EPE) in order to guide
nerve-sparing surgery. Data were collected from chart review.
MRI AND RSI
Patients underwent standard T2,perfusion (with Gadolinium) and
diffusion protocols at 3 T (Siemens, Erlangen Germany) with an
endorectal coil prior to radical prostatectomy. Table 1 shows pulse
sequence details. A modified Prostate Imaging-Reporting and Data
System (PIRADS) score, termed “the UCLA assessment criteria,”
was assigned to the scan based on the suspicion of cancer pre-
viously instituted at our institution (17). The ADC maps used
to draw ROIs were generated from the low b-value, 800 s/mm2,
derived from the same spectrum of b-values used in the RSI pro-
tocol. ADC maps were corrected for spatial distortion (18). The
restriction spectrum diffusion tensor imaging protocol parameters
include b-values of 0, 800, 1500, 4000 s/mm2 in 30 unique diffu-
sion directions for each non-zero b-value. RSI cellularity maps
were reconstructed based on all b-values (8). The RSI cellularity
maps were then standardized across the sample, using the mean
and standard deviations of normal prostate signal from the raw
Table 1 | MRI scan parameters for prostate MRI protocol at 3T.
Pulse sequence Parameters
T2 Axial 3D TSE T2 (Siemens SPACE), TR/TE
3800-5040/101, ETL 13, 14 cm FOV, 256×256
matrix, 1.5 mm contiguous slices
Diffusion-weighted
(standard)
echoplanar, TR/TE 3900/60, 21×26 cm FOV,
130×160 matrix, 3.6 mm slices, 4 NEX,
b-values 0, 100, 400, 800 s/mm2
T1 dynamic perfusion
imaging
Siemens TWIST, TR/TE 3.9/1.4 ms, 12° flip angle,
26×26 cm FOV, 160×160 matrix, 3.6 mm
slices, 4.75 s/acquisition over 6 minutes with
15 s injection delay, image analysis using iCAD
Versavue
Restriction spectrum
imaging
Spin echo EPI, TR/TE 5500/137, 26 cm×26 cm
FOV, 128×96 matrix, 3.6 mm slices, 30
directions at each b-value, b-values 0, 800,
1500, 4000 s/mm2
RSI maps in 20 patients to produce z-score maps. RSI maps were
also corrected for spatial distortion (19).
PATHOLOGY
After prostatectomy, whole-mount histopathology was routinely
performed on 4µm thick sections of each specimen. A Gleason
score was assigned to each representative tumor location. If two
tumors were located, the Gleason score for each was assessed inde-
pendently. The histopathology was evaluated and the boundaries
of tumor vs. benign tissue were identified by an uropathologist.
OUTCOMES
We defined our primary outcome as pathologic primary Gleason
score of 4, which means that Gleason 4 is the dominant histologic
architecture and includes 4+ 3, 4+ 4, and 4+ 5 Gleason patterns.
The pathologic Gleason score is currently the standard of refer-
ence for PCa aggressiveness. Additionally, the ability of imaging
to detect secondary Gleason patterns may be minimal; therefore,
herein we focus on primary Gleason patterns. Our primary pre-
dictor variable was the normalized cellularity index called the “RSI
z-score.” The most commonly utilized tool to identify and classify
aggressive cancer on MRI currently is the ADC value from DWI;
therefore, the RSI z-score was compared with ADC to assess the
predictive value in differentiating cancer from normal ROI.
Each patient had at least one identified region of cancerous
tissue. If two areas of cancer were detected, each region was eval-
uated and assigned a separate Gleason score, ADC, and z-score.
Tumor ROIs were drawn based on the pathology in combination
with ADC images that had been corrected for spatial distortion.
A benign ROI was defined in a region of the prostate seen to be
free of PCa on the whole-mount histology. ADC and RSI z-score
values were recorded for all ROIs.
STATISTICAL ANALYSIS
Each patient had at least one ROI of cancer and one ROI of benign
tissue. Correlation between the RSI-derived z-score and ADC was
determined by a Pearson correlation test assuming normal dis-
tribution. In order to investigate the association of RSI z-score
and primary Gleason pattern 4 PCa vs. pattern 3 PCa, a t -test
was performed. In order to compare the utility of MRI techniques
(RSI z-score vs. ADC) for detecting aggressive cancer, we com-
pared ROIs representing pathologically benign tissue with those
representing increasing aggressive PCa (benign vs. Gleason 3 vs.
Gleason 4 primary patterns) using ANOVA analysis (F-test). After
removing the values for the benign ROIs, we also assessed variation
in MRI values among different grades of cancerous tissue aggres-
siveness by performing a comparative t -test. Multivariable analysis
included an ordinal logistic regression (benign vs. Gleason 3 vs.
Gleason 4) and binary logistic regression (Gleason 3 vs. Gleason
4). p-values <0.05 were considered statistically significant using
the statistical package SPSS v.21 (IBM, Chicago, IL, USA). Age and
race were controlled for due to the risk of PCa associated with
these variables and that they are inherent to each ROIs. However,
other demographic variables associated with cancer (PSA, clinical
stage, biopsy data, etc.) may not be associated with an individual
ROI and may misrepresent the data as some patients have multi-
ple ROIs. Therefore, the multivariable analysis only includes the
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preselected variables of age and race without accounting for these
other variables despite their significance in univariable analysis.
RESULTS
After IRB approval (UCLA IRB#12-001301), we identified 28
patients who underwent preoperative MRI with RSI and subse-
quent whole-mount pathology after radical prostatectomy, with
surgery taking place between May 2012 and May 2013. Demo-
graphics are displayed in Table 2. Figure 1 shows representative
examples of RSI across the Gleason spectrum and illustrates data
collection methods. White arrows within the higher-grade RSI
maps show areas of signal void that could be interpreted as false
positives on the corresponding ADC maps. We identified 64 ROIs
(28 benign and 36 PCa). Eight patients had two distinct tumor
ROIs within one specimen. Seven of those patients had discor-
dant tumors (two different Gleason scores) and only one patient
had two concordant tumor ROIs (both Gleason 3+ 4). The RSI
z-score data for all ROIs, grouped by Gleason score, is shown in
Figure 2.
Apparent diffusion coefficient and RSI z-scores are normally
distributed and did not need further transformation. There is
a significant correlation between ADC and RSI z-score (Pear-
son R= 0.69; n= 64, p< 0.001) (see supplementary figure). ADC
and RSI z-score are collinear (collinearity index 8.4); therefore,
they cannot be placed within the same multivariate analytic
model.
The mean cellularity index (RSI z-score) in PCa was 2.53
(SE= 0.10) and in benign tissue 0.39 (SE= 0.12; p< 0.001). The
mean ADC for PCa was 1169 mm2/s (SE= 67 mm2/s) and benign
was 1679 mm2/s (SE= 81 mm2/s, p< 0.001).
For the univariate and multivariate analyses, the data were
grouped by primary Gleason pattern, either primary Gleason 3
(3+ 3 or 3+ 4) or Gleason 4 (4+ 3, 4+ 4, or 4+ 5). In univari-
able analysis, we investigate the association of RSI z-score and
ADC with PCa on pathology (benign vs. Gleason 3 vs. Gleason
4) using ANOVA analysis. Both were able to distinguish benign
from increasingly malignant PCa (both p< 0.001) (Table 3).
Figure 3 displays a box plot developed from individual ROI RSI z-
scores corresponding to benign tissue primary Gleason 3 pattern
or primary Gleason 4 pattern PCa tumors. When removing the
benign ROIs as to only compare low-grade (primary Gleason 3)
to high-grade PCA (primary Gleason 4), RSI technique was able
Table 2 | Demographics: perioperative demographics for 28 patients who underwent MRI with an endorectal coil and subsequently underwent
radical prostatectomy.
Age Race BMI PSA Clinical
Stage
Biopsy
Gleason
Positive
cores
Maximum
percent
cancer %
Imaging
criteria
Pathologic
Gleason
Pathologic
stage
63 White 20.1 7 T1c 3+4 3 of 15 30 4 3+3 T2
61 White 31.4 5.8 T1c 4+3 4 of 12 85 5 3+4 T3b
55 White 29.3 2.8 T1c 3+5 4 of 12 90 3 3+4 T3a
71 White 29.7 7.3 T2 3+3 9 of 19 60 3 3+4 T2
59 White 31.4 4.43 T2 3+3 4 of 12 33 3 3+4 T2c
61 White 21.4 9.2 T2 3+3 6 of 15 30 4 3+4 T2b
68 White – 6.7 T1c 3+4 10 of 12 70 3 3+4 T2c
55 White 27.5 4.7 T1c 3+4 6 of 16 70 3 3+4 T2b
64 White 23.1 5.8 T1c 3+4 1 of 12 30 2 3+4 T2c
61 Other 26 3.4 T1c 3+4 6 of 13 95 3 3+4 T2c
60 Unknown 25.5 6 T1c 3+3 3 of 12 – 3 3+4 T2
61 White 29.8 6.6 T1c – – – 4 3+4 T2
65 Unknown 29 5.4 T2 3+4 2 of 14 45 2 3+4 T2
50 White 31.2 8.9 T1c 3+4 2 of 12 20 4 3+4 T2
53 White 22.7 3.9 T1c 4+3 3 of 8 15 2 3+4 T3a
44 White 26.6 2.8 T1c 3+4 4 of 16 70 3 3+4 T2a
58 White 32.7 3.8 T1c 3+4 6 of 12 70 3 3+4 T2c
53 Asian 16.9 5.5 T1c 3+4 3 of 12 15 4 3+4 T2
62 African American 25.1 4.8 T1c 4+3 2 of 12 70 0 4+3 T2a
65 White 38.5 5.8 T2 4+3 5 of 12 88 5 4+3 T3a
64 White 26.9 4.2 T1c 3+5 12 of 12 94 5 4+3 T3a
56 Other 28 11.5 T1c 3+4 multiple 50 4 4+3 T3a
67 White 30.4 5.1 T1c 3+4 5 of 13 25 4 4+3 T3a
71 White 28.4 12.8 T1c 4+3 – – 5 4+3 T3a
45 African American 23.5 6.5 T1c 4+3 9 of 16 80 1 4+4 T2c
65 White 30.1 8.2 T1c 5+4 – 55 4 4+5 T3b
62 White 25.8 4.6 T2 4+5 5 of 15 50 4 4+5 T2
70 Filipino 35.5 7.5 T2 4+3 9 of 12 90 3 4+5 T3a
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to distinguish the two groups (p= 0.03) and ADC trended to sig-
nificance (p= 0.08). We then investigated these same parameters
in multivariable analysis and determined that both RSI z-score
FIGURE 1 | Representative images showing RSI z-score maps across
Gleason scores: the y -axis shows the pathologic Gleason score with
the x -axis designating the MRI sequence. The last column displays the
whole-mount pathology with the corresponding cancer region of interest
circled in black. The star in the top right pathologic figure represents the
pattern 3+3 prostate cancer while the other lesions are 4+ 3. White
arrowheads in the higher-grade patients show areas of signal void, which
could be interpreted as false positives on the ADC maps.
and ADC were able to distinguish between the three groups in
ordinal regression analysis adjusting for age and race (white vs.
non-white); though the log odds of the parameter estimates sug-
gest an improved distinction of the groups by RSI (RSI z-score
and ADC, p< 0.001). However, when determining the difference
in the detection of low-grade and high-grade PCa, a higher RSI
z-score was significantly associated with the higher-grade primary
Gleason 4 pattern [Odds ratio 10.3 (1.4–78.0; p= 0.02)] and ADC
showed a trend in distinguishing between the two Gleason patterns
(p= 0.07) (Table 4).
DISCUSSION
Magnetic Resonance RSI normalized cellularity index (RSI z-
score) is able to distinguish aggressive PCa (primary Gleason score
of 4 compared to 3) in our population of men undergoing rad-
ical prostatectomy. Importantly, the RSI technique has displayed
at least similar ability to distinguish Gleason grade to the current
reference standard, ADC values.
Multiple studies have described the ability of ADC to detect
PCa. However, the distinction between PCa aggressiveness has
been less investigated. Donati et al. found that mean ADC could
distinguish Gleason 6 from 7+ tumors in 131 men under-
going prostatectomy (AUC 0.706) and in another paper dis-
cussed the use of 10th percentile ADC correlation to aggres-
siveness (10, 16). The 10th percentile ACD was also used
in combination with mean ADC, T2-weighted skewness, and
K trans to distinguish PCa using computer aided diagnosis (18).
Moreover, a recent study has suggested that ADC entropy
rather than mean ADC could better discriminate the pro-
portion of Gleason 4 cancer among Gleason 3+ 4 and 4+ 3
tumors (20). The distinction in primary Gleason pattern may
FIGURE 2 | RSI z-score value grouped by pathologic Gleason score: the
y -axis represents the RSI z-score derived from a given region of interest.
The x -axis demonstrates the pathological Gleason scores in increasing levels
of aggressiveness from left to right. Each data point represents one region of
interest corresponding to a location on the whole-mount prostatectomy
specimen contoured by a GU pathologist.
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Table 3 | Univariable analysis: restriction spectrum imaging (RSI) z-score and apparent diffusion coefficient (ADC) are independently
investigated comparing individual regions of interest to their corresponding primary Gleason pattern.
Sample size method Means Statistical test p value
Detection of increasingly aggressive cancera Mean (standard error) F -test
64 Restricted spectrum imaging (RSI) z -score 97.7 <0.001
Benign 0.65 (0.12)
Primary Gleason 3 2.4 (0.61)
Primary Gleason 4 2.9 (0.51)
64 Apparent diffusion coefficient (ADC) 13.9 <0.001
Benign 1680 (428)
Primary Gleason 3 1237 (425)
Primary Gleason 4 967 (221)
Prostate cancer aggressivenessb Mean difference t -test
36 Restricted spectrum imaging (RSI) z -score 34 0.5 2.22 0.033
36 Apparent diffusion coefficient (ADC) 34 269 1.81 0.079
The top half of the table uses ANVOA analysis to determine differences in detection comparing benign vs. primary Gleason 3 vs. Primary Gleason 4 prostate cancer.
The bottom half of the table only compares Gleason 3 vs. 4 cancers with a t-test.
aBenign vs. Gleason 3 vs. Gleason 4.
bGleason 3 vs. Gleason 4.
FIGURE 3 | Box plot of RSI z-score for primary Gleason pattern: the box plot represents the RSI z-score for benign, pathologic primary pattern
Gleason 3, or pathologic primary pattern Gleason 4 prostate cancer.
have significant clinical implications regarding PCa management
decision-making.
Primary Gleason 4 pattern is a more aggressive cancer with
patients experiencing higher rates of biochemical (PSA) failure
after prostatectomy, systemic recurrence, and PCa mortality (21).
Therefore, knowledge of high-grade cancer prior to making man-
agement decisions would be helpful in determining treatment
strategy. For example, men without Gleason 4 pattern PCa are
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Table 4 | Multivariable analysis: restriction spectrum imaging (RSI) z-score and apparent diffusion coefficient (ADC) are independently
investigated comparing individual regions of interest to their corresponding primary Gleason pattern.
Sample size method Parameter coefficienta
(95% confidence interval)
p value McFadden’s D
Detection of increasingly aggressive prostate cancerb
64 Restricted spectrum imaging (RSI) z -score <0.001 0.613
Benign 0
Primary Gleason 3 9.5 (−1.9 to 17.0) 0.014
Primary Gleason 4 15.8 (6.4–25.2) 0.001
64 Apparent diffusion coefficient (ADC) <0.001 0.202
Benign 0
Primary Gleason 3 1.7 (−3.2 to 6.7) 0.483
Primary Gleason 4 4.5 (−0.5 to 9.6) 0.076
Prostate cancer aggressivenessc Wald test Odds ratio
(95% confidence interval)
p value
36 Restricted spectrum imaging (RSI) z -score 5.1 10.3 (1.4–78.0) 0.024
36 Apparent diffusion coefficient (ADC) 3.3 0.9 (0.9–1.00) 0.069
The top half of the table uses ordinal logistic regression analysis to determine differences in detection comparing benign vs. primary Gleason 3 vs. Primary Gleason
4 prostate cancer (Log Odds). The bottom half of the table only compares Gleason 3 vs. 4 cancers to determine with binary logistic regression (Odds Ratio).
aParameter coefficients are the log odds and can be converted to odds ratios by taking the exponent of the estimate. The numbers are too large therefore are kept
as log odds for simplicity.
bOrdinal logistic regression (benign vs. Gleason 3 vs. Gleason 4) adjusting for age and race (White vs. Non-White).
cBinary logistic regression (Gleason 3 vs. Gleason 4) adjusting for age and race (White vs. Non-White).
more ideal candidates for active surveillance (22). Serial imaging
may indicate progression of disease, assisting urologists in decid-
ing when a biopsy-off of protocol is warranted. Additionally,
PCa grade may influence the urologic surgeon to perform a
pelvic lymph node dissection at the time of prostatectomy due
to increased risk of nodal disease (23).
Currently, ADC serves as the most discriminatory parameter
to assist radiologists for the detection of cancer. Moreover, recent
examination of ADC and PCa has shown the association of ADC
and PCa aggressiveness (10, 16). While we do show that ADC can
differentiate the presence of cancer or not, our study shows that
ADC is less able to determine the subtlety of primary pattern Glea-
son 3 vs. Gleason 4 PCa. Possible reasons include the proportion
of pattern 3 vs. 4 disease in our population compared to prior pop-
ulations, the b-values used in determining the ADC, how the ROI
was chosen, the amount of stromal reaction, and technical factors
such as degree of hemorrhage. However, the differences between
ADC and RSI z-score in our study are small.
Restriction spectrum imaging techniques offer advantages
when compared to conventional DWI and ADC maps. For exam-
ple, one of the challenges of standard diffusion imaging is that the
ADC values are not standardized across MRI scanners. The z-score
is a standardized statistical method and inherently normalizes
across the patient pool. Thus, the RSI z-score is a value that could
potentially be compared across different scanners and institutions
and provide a more robust value for relative comparison.
In addition, conventional DWI/ADC suffers from geomet-
ric distortion and can be difficult to interpret by clinicians
and untrained radiologists. Distortion correction techniques
previously optimized in the brain for GBM, are incorporated
into our RSI post-processing stream in order to derive spa-
tially corrected cellularity maps. Distortion correction tech-
niques are not routinely employed in conventional DWI and
resultant ADC maps. Thus, the RSI maps can be co-registered
with T2-weighted anatomic images with voxel accuracy. This
has potential implications for more accurate detection of
EPE and more accurate MRI-fused ultrasound targeted biopsy
results (24).
Because of its greater sensitivity to restricted rather than hin-
dered diffusion, RSI may be less subject to hemorrhage, inflam-
matory processes, and benign nodules in the transitional zone, all
of which can exhibit lower ADC values leading to false positives.
Theoretically, RSI-MRI reduces extracellular signal by focusing
on the signal emanating from intracellular tumor cells (restricted
diffusion) and less from the extracellular signal (hindered diffu-
sion) (8, 9). This will need to be rigorously tested in future ROC
performance studies.
Apparent diffusion coefficient maps will exhibit low signal in
regions where there is overt chemical dephasing from gross cal-
cium, hemorrhage, or other etiologies resulting in signal void.
Unfortunately, these signal voids could be interpreted inaccurately,
leading to a false positive result. White arrow heads in Figure 1
show two such examples. For example, in the Gleason 5+ 4 case,
the anterior region of signal void shows up as dark (low) on the
ADC maps, potentially a false positive, while in the RSI maps, this
is clearly interpreted as an area of signal void, not tumor. Thus,
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RSI offers a number of potential advantages when compared to
DWI/ADC.
Certain limitations of this study include small sample size
and retrospective data collection. We have overcome the small
sample size by using each patient as his own control to pro-
vide a paired analysis by using known benign tissue. However,
because of the small sample size, we have fewer patients with
extremely high-grade cancer (Gleason 5) and low-grade (Glea-
son 6 or less); therefore, we dichotomized based on the primary
Gleason pattern. We justify this analysis by assuming that MRI
imaging is unlikely to visualize smaller amounts (secondary pat-
terns) of PCa architecture. The sample size was too small to
evaluate upgrading or downgrading Gleason scores at prosta-
tectomy from the initial biopsy results in order to determine
if RSI could serve to differentiate these cases; however, this
question will serve as a focus in future studies. We do have a
selection bias regarding our patient population as all patients
underwent radical prostatectomy. Therefore, our results may not
necessarily apply to patients in the general PSA screening pop-
ulation undergoing prostate biopsy. The lack of patients in this
study with pathologies at the extremes shows the need for a
broader study.
CONCLUSION
Restriction Spectrum Imaging cellularity index is associated with
the detection of aggressive PCa as defined by Gleason score.
Additionally, RSI-MRI includes correction of spatial distortion,
a normalized measure of cellularity, and in general increased
conspicuity when compared to conventional DWI/ADC. RSI
technology warrants prospective evaluation in the PCa diagnos-
tic arena.
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